BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsai HI, Liu FC, Lee CW, Kuo CF, See LC, Chung TT, Yu HP. Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study. Transpl Int. 2017;30:1161-1171. [PMID: 28691253 DOI: 10.1111/tri.13010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiao J, Yong JN, Ng CH, Syn N, Lim WH, Tan DJH, Tan EY, Huang D, Wong RC, Chew NWS, Tan EXX, Noureddin M, Siddiqui MS, Muthiah MD. A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver Transpl 2021. [PMID: 34626045 DOI: 10.1002/lt.26331] [Reference Citation Analysis]
2 Schwarzenbach M, Bernhard FE, Czerlau C, Sidler D. Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures. World J Transplant 2021; 11(7): 254-262 [PMID: 34316450 DOI: 10.5500/wjt.v11.i7.254] [Reference Citation Analysis]
3 Vinson AJ, Dai R, Agarwal G, Anzalone AJ, Lee SB, French E, Olex AL, Madhira V, Mannon RB; National COVID Cohort Collaborative (N3C) Consortium. Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19. Am J Transplant 2021. [PMID: 34637599 DOI: 10.1111/ajt.16865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lukaszewski M, Kosiorowska K, Kaminska D, Obremska M, Mazanowska O, Krajewska M. Myocardial remodeling after kidney transplantation: a case report. BMC Nephrol 2018;19:372. [PMID: 30572818 DOI: 10.1186/s12882-018-1185-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Iannuzzo G, Cuomo G, Di Lorenzo A, Tripaldella M, Mallardo V, Iaccarino Idelson P, Sagnelli C, Sica A, Creta M, Baltar J, Crocetto F, Bresciani A, Gentile M, Calogero A, Giallauria F. Dyslipidemia in Transplant Patients: Which Therapy? JCM 2022;11:4080. [DOI: 10.3390/jcm11144080] [Reference Citation Analysis]
6 Pfrepper C, Herber A, Weimann A, Siegemund R, Engelmann C, Aehling N, Seehofer D, Berg T, Petros S. Safety and efficacy of direct oral anticoagulants under long-term immunosuppressive therapy after liver, kidney and pancreas transplantation. Transpl Int 2021;34:423-35. [PMID: 33336411 DOI: 10.1111/tri.13804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Warden BA, Duell PB. Management of dyslipidemia in adult solid organ transplant recipients. J Clin Lipidol. 2019;13:231-245. [PMID: 30928441 DOI: 10.1016/j.jacl.2019.01.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
8 Cuomo G, Cioffi G, Di Lorenzo A, Iannone FP, Cudemo G, Iannicelli AM, Pacileo M, D’andrea A, Vigorito C, Iannuzzo G, Giallauria F. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients. JCM 2022;11:3247. [DOI: 10.3390/jcm11113247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]